Form 4: Adverum Biotechnologies COO Acquires Shares and Options

Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, reports acquisition of shares and stock options.

Summary

• Peter Soparkar, the Chief Operating Officer of Adverum Biotechnologies, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 13,125 shares of common stock related to a restricted stock unit (RSU) grant vesting over three years from March 1, 2025.
• Soparkar also acquired options to purchase 78,750 shares of common stock at an exercise price of $4.20, vesting over four years from March 1, 2025.
• The filing also notes that Soparkar directly owns 42,114 shares of Adverum Biotechnologies common stock, including shares purchased through the company's employee stock purchase plan.
• A 1-for-10 stock split on March 21, 2024, resulted in a proportionate reduction of the reporting person's shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of shares and options by the COO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSU grant and stock options extend over the next several years, contingent on the Reporting Person's continued service with the Issuer.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders gain insight into the transactions of company insiders, which can influence investor sentiment.

Key Dates